This is an old revision of the document!
Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)
On April 17, 2020, the National Institutes of Health (NIH) announced the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership to develop a coordinated research strategy for prioritizing and speeding up development of COVID-19 vaccines and pharmaceutical products.1)
ACTIV is a collaboration with the Foundation for the National Institutes of Health (FNIH), Biomedical Advanced Research and Development Authority (BARDA), Centers for Disease Control and Prevention (CDC), the U.S. Food and Drug Administration (FDA), the US Department of Defense (DOD), the Department of Veterans Affairs (VA), Countermeasures Acceleration Group (formerly Operation Warp Speed), and the European Medicines Agency (EMA).
Membership
ACTIV Executive Committee
The ACTIV Executive Committee is made up of representatives from various agencies of the U.S. government and pharmaceutical companies.2)
| Name | Organization | Role |
|---|---|---|
| Larry Tabak | National Institutes of Health (NIH) | Co-Chair |
| William Pao | Roche | Co-Chair |
| Gary Disbrow | BARDA | Member |
| Mikael Dolsten | Pfizer | Member |
| Anthony Fauci | National Institutes of Health (NIH) | Member |
| Gary Gibbons | National Institutes of Health (NIH) | Member |
| Peter Marks | Food and Drug Administration (FDA) | Member |
| Gary Dubin | Takeda | Member |
| Janet Woodcock | Food and Drug Administration (FDA) | Member |
Preclinical Working Group
| Name | Organization | Role |
|---|---|---|
| Peter Adams3) | Department of Health of Human Services (HHS) | Health Scientist, Influenza Division; Biomedical Advanced Research and Development Authority |
| Annaliesa Anderson | Pfizer | Vice President and Chief Scientific Officer, Bacterial Vaccines |
| James Anderson | National Institutes of Health (NIH) | Director, Division of Program Coordination, Planning, and Strategic Initiatives; Office of the Director |
| Ralph Baric | University of North Carolina | Professor, Deptartment of Epidemiology and Deptartment of Microbiology and Immunology |
| Kara Carter | Dewpoint Therapeutics | Senior Vice President, Discovery Biology |
| Marc Charette | National Heart, Lung, and Blood Institute | Program Director; Division of Cardiovascular Diseases |
| Tomas Cihlar | Gilead Sciences | Vice President and Head of Virology |
| Christine Colvis | National Center for Advancing Translational Sciences | Director, Drug Development Partnership Programs]] |
| Michael Diamond | Washington University School of Medicine in St. Louis | The Herbert S. Gasser Professor, Departments of Medicine, Molecular Microbiology, Pathology & Immunology |
| Ken Duncan | Bill & Melinda Gates Foundation | Deputy Director, Discovery – Therapeutics |
| Prabhavathi Fernandes | National Biodefense Science Board | SAC of GARDP, Chair |
| Joshua Fessel | National Heart, Lung, and Blood Institute | Program Director, Lung Vascular Biology Program; Division of Lung Disease |
| Clint Florence | National Institute of Allergy and Infectious Diseases (NIAID) | Program Officer, Research Resource Section, OBRR, DMID |
| Greg Gatto | RTI International | Drug Development Regulatory Project Leader |
| Jay Grobler | Merck | Executive Director, Infectious Disease and Vaccines |
| Nancy Haigwood | Oregon National Primate Research Center; Oregon Health & Science University | Director and Professor |
| Judith Hewitt | National Institute of Allergy and Infectious Diseases (NIAID) | Deputy Director, Office of Biodefense, Research Resources and Translational Research |
| Sheri Hild | National Institutes of Health (NIH) | Program Director for National Primate Research Centers; Office of Research and Infrastructure Program |
| Samantha Jonson | National Center for Advancing Translational Sciences | Special Assistant to the Director |
| Isis Kanevsky | Pfizer | Director |
| Kent Lloyd | University of California, Davis | Professor, Department of Surgery, School of Medicine Director, Mouse Biology Program; Associate Director, Comprehensive Cancer Center |
| Joanne Lumsden | National Center for Advancing Translational Sciences | Senior Scientific Program Manager, Drug Development Partnership Programs |
| Cat Lutz | Jackson Laboratory | Senior Director, Mouse Repository & In Vivo Pharmacology, Rare and Orphan Disease Center |
| Stephen Mason | Pfizer | Research Associate & Viral Drug Discovery Fellow |
| Frank Nestle | Sanofi | Global Head of Immunology Therapeutic Research Area and Chief Scientific Officer North America |
| Elizabeth Ottinger | National Center for Advancing Translational Sciences | Senior Program Manager, Division of Preclinical Innovation |
| David Payne | GlaxoSmithKline | Vice President & Head, Medicine Opportunities Research Unit |
| Louise Pitt | United States Army Medical Research Institute of Infectious Diseases | Director, Center for Aerobiological Sciences |
| Antonello Punturieri | National Heart, Lung, and Blood Institute | Program Director, Division of Lung Diseases |
| Srinivas Rao | Sanofi | Global Head, Translational In Vivo Models Global Research Platform |
| Jay Rappaport | Tulane University National Primate Research Center | Professor of Microbiology and Immunology; Director and Chief Academic Officer |
| John Young | Roche | Global Head Infectious Diseases and Vice President |
| Roland Zahn | Janssen | Senior Scientific Director; Head Preclinical Immunology, Viral Vaccines |
1)
ACTIV. National Institutes of Health (NIH). Retrieved April 1, 2022, from https://archive.ph/8eMTV
2)
ACTIV Public-Private Partnership. (2022). National Institutes of Health. https://web.archive.org/web/20220402051949/https://www.nih.gov/sites/default/files/research-training/initiatives/activ/activ-org-chart_3.2.22.pdf
3)
Preclinical Working Group. (2022, March 8). National Institutes of Health (NIH). https://archive.ph/dvDVw